Chargement en cours...
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
INTRODUCTION: Nintedanib slows disease progression in patients with idiopathic pulmonary fibrosis (IPF) by reducing the rate of decline in forced vital capacity, with an adverse event profile that is manageable for most patients. We used data from six clinical trials to characterise the safety and t...
Enregistré dans:
| Publié dans: | BMJ Open Respir Res |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6530503/ https://ncbi.nlm.nih.gov/pubmed/31179001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2018-000397 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|